AU2013336293B2 - Use of a tetrasubstituted pyrazolo(4,3-d)pyrimidine compound for treating diabetic nephropathy - Google Patents

Use of a tetrasubstituted pyrazolo(4,3-d)pyrimidine compound for treating diabetic nephropathy Download PDF

Info

Publication number
AU2013336293B2
AU2013336293B2 AU2013336293A AU2013336293A AU2013336293B2 AU 2013336293 B2 AU2013336293 B2 AU 2013336293B2 AU 2013336293 A AU2013336293 A AU 2013336293A AU 2013336293 A AU2013336293 A AU 2013336293A AU 2013336293 B2 AU2013336293 B2 AU 2013336293B2
Authority
AU
Australia
Prior art keywords
amino
pyrazolo
ethyl
pyrimidine
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2013336293A
Other languages
English (en)
Other versions
AU2013336293A1 (en
Inventor
Valerie Clerin
Jeremy GALE
Nihad TAMIMI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Publication of AU2013336293A1 publication Critical patent/AU2013336293A1/en
Application granted granted Critical
Publication of AU2013336293B2 publication Critical patent/AU2013336293B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2013336293A 2012-10-23 2013-10-09 Use of a tetrasubstituted pyrazolo(4,3-d)pyrimidine compound for treating diabetic nephropathy Expired - Fee Related AU2013336293B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261717429P 2012-10-23 2012-10-23
US61/717,429 2012-10-23
PCT/IB2013/059239 WO2014064566A1 (en) 2012-10-23 2013-10-09 Use of a tetrasubstituted pyrazolo[4,3-d]pyrimidine compound for treating diabetic nephropathy

Publications (2)

Publication Number Publication Date
AU2013336293A1 AU2013336293A1 (en) 2015-04-09
AU2013336293B2 true AU2013336293B2 (en) 2016-05-12

Family

ID=49765599

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013336293A Expired - Fee Related AU2013336293B2 (en) 2012-10-23 2013-10-09 Use of a tetrasubstituted pyrazolo(4,3-d)pyrimidine compound for treating diabetic nephropathy

Country Status (15)

Country Link
US (2) US20150274735A1 (enExample)
EP (1) EP2911672A1 (enExample)
JP (1) JP2015534977A (enExample)
KR (1) KR20150056853A (enExample)
CN (1) CN104755086A (enExample)
AU (1) AU2013336293B2 (enExample)
BR (1) BR112015008380A2 (enExample)
CA (1) CA2888160A1 (enExample)
HK (1) HK1211850A1 (enExample)
IL (1) IL238374A0 (enExample)
IN (1) IN2015DN03190A (enExample)
MX (1) MX2015005004A (enExample)
RU (1) RU2015115005A (enExample)
SG (1) SG11201502286XA (enExample)
WO (1) WO2014064566A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101939328B1 (ko) * 2012-12-21 2019-01-16 주식회사 엘지화학 신규한 구조를 가지는 중공사막 및 그 제조 방법
WO2020166710A1 (ja) 2019-02-15 2020-08-20 国立大学法人東北大学 １，３－ジオキソラン誘導体

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006016262A1 (en) * 2004-08-10 2006-02-16 Pfizer Limited Combination of a selective noradrenaline reuptake inhibitor and a pdev inhibitor
WO2007054778A1 (en) * 2005-11-10 2007-05-18 Pfizer Products Inc. Pyrazolo[4,3-d]pyrimidin-5-yl)derivative used as pde5 inhibitors
US20080194591A1 (en) * 2005-05-12 2008-08-14 Pfizer Inc. Anhydrous Crystalline Forms Of N-[1-(2-Ethoxyethyl)-5-(N-Ethyl-N-Methylamino)-7-(4-Methylpyridin-2-Yl-Amino)-1H-Pyrazolo[4,3-D]Pyrimidine-3-Carbonyl]Methanesulfonamide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
SI1881985T1 (sl) * 2005-05-12 2011-03-31 Pfizer Brezvodne kristalinične oblike N-1-(2-etoksietil)-5(N-etil-N-metilamino)-7-(4-metilpriridin-2-il-amino) -1H-pirazolo(4,3-d)pirimidin-3-karbonil"metansulfonamida

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006016262A1 (en) * 2004-08-10 2006-02-16 Pfizer Limited Combination of a selective noradrenaline reuptake inhibitor and a pdev inhibitor
US20080194591A1 (en) * 2005-05-12 2008-08-14 Pfizer Inc. Anhydrous Crystalline Forms Of N-[1-(2-Ethoxyethyl)-5-(N-Ethyl-N-Methylamino)-7-(4-Methylpyridin-2-Yl-Amino)-1H-Pyrazolo[4,3-D]Pyrimidine-3-Carbonyl]Methanesulfonamide
WO2007054778A1 (en) * 2005-11-10 2007-05-18 Pfizer Products Inc. Pyrazolo[4,3-d]pyrimidin-5-yl)derivative used as pde5 inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MENNITI, F. S. et al. "A non-brain penetrant PDE5A inhibitor improves functional recovery after stroke in rats" Restorative Neurology and Neuroscience (2012) vol. 30, pages 283-289 *

Also Published As

Publication number Publication date
CA2888160A1 (en) 2014-05-01
WO2014064566A1 (en) 2014-05-01
SG11201502286XA (en) 2015-05-28
MX2015005004A (es) 2015-07-17
US20150274735A1 (en) 2015-10-01
BR112015008380A2 (pt) 2017-07-04
HK1211850A1 (en) 2016-06-03
JP2015534977A (ja) 2015-12-07
CN104755086A (zh) 2015-07-01
KR20150056853A (ko) 2015-05-27
RU2015115005A (ru) 2016-12-20
AU2013336293A1 (en) 2015-04-09
US20160136170A1 (en) 2016-05-19
IN2015DN03190A (enExample) 2015-10-02
IL238374A0 (en) 2015-06-30
EP2911672A1 (en) 2015-09-02

Similar Documents

Publication Publication Date Title
Sun et al. Cyclopropyl scaffold: A generalist for marketed drugs
SG188238A1 (en) Combination therapy for treating hcv infection
CN111249282B (zh) 癌症疗法
AU716519B2 (en) Method of treating renal disease using an ace inhibitor and an A II antagonist
AU2004283047B2 (en) Pharmaceutical composition comprising a selective I1 imidazoline receptor agonist and an angiotensin II receptor blocker
AU2013336293B2 (en) Use of a tetrasubstituted pyrazolo(4,3-d)pyrimidine compound for treating diabetic nephropathy
KR20050106038A (ko) 심장질환 및 신장질환의 치료를 위한 아데노신 ａ1 수용체길항제
WO2010097501A2 (en) A combination treatment
EP2837380B1 (en) Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof
JP2006517557A (ja) 脳卒中発作予防のための、アセチルサリチル酸およびアンジオテンシンｉｉ拮抗薬と組み合わせたジピリダモールの使用
US20080096915A1 (en) Compositions for the treatment of metabolic disorders
WO2014141295A2 (en) Treatment and prophylaxis of kidney diseases
CN105025895A (zh) 用于治疗肺动脉高压和肺损伤的1,3-二氢咪唑-2-硫酮衍生物
US20100249103A1 (en) combination treatment
CA2946151C (en) Stable solid immunosuppressor composition
WO2011027021A1 (en) A method for the treatment of hypertension
Kondo et al. The discovery of Samsca®(Tolvaptan): the first oral nonpeptide vasopressin receptor antagonist
EP4525857A1 (en) Methods of treating focal segmental glomerulosclerosis with atrasentan
HK40030002B (zh) 癌症疗法
CN101163705A (zh) 组合产品

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee